InflaRx ends its Phase 3 trial of vilobelimab in pyoderma gangrenosum and shifts focus to INF904 amid efforts to extend its ...

InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement ...

Treatment of PG is currently limited to immune-suppressing drugs and antibiotics to treat complicating infections, and, in ...

InflaRx’s vilobelimab met the bar for futility in a Phase III trial for the rare skin disease pyoderma gangrenosum.

InflaRx (IFRX) stock falls as the company decided to halt studies into its lead asset vilobelimab against pyoderma ...

After a poor showing of its COVID med vilobelimab in a rare skin disorder trial, German drugmaker InflaRx is going back to ...

German drug developer InflaRx (Nasdaq: IFRX) saw its US-traded shares plunge 55% to $0.82 in pre-market activity today, as it ...

Backers of Jena, Germany-based Inflarx NV have turned their attention to the rest of the pipeline after the stock-jolting news from an independent data monitoring committee (DMC) responsible for the ...

announced Wednesday that the Independent Data Monitoring Committee or IDMC conducting the unblinded interim analysis for the Phase 3 trial for vilobelimab in pyoderma gangrenosum or PG recommended ...

Prof. Niels C. Riedemann, Chief Executive Officer and Founder of InflaRx, said: “We would like to thank the dedicated physicians and pyoderma gangrenosum patients for their participation in this ...